Plant extract hydrolysates and antibacterial product containing the same

Abstract

The invention relates to a hydrolyzate from at least one extract of at least one plant material selected from the group consisting of at least one genus: Equiseti, Juglandis, Millefolii, Quercus, Taraxaci, Althaeae, Matricariae, Centaurium, Levisticum, Rosmarinus, Angelica ( e ), Artemisia, Astragalus, Leonurus, Salvia, Saposhnikovia, Scutellaria, Siegesbeckia, Armoracia, Capsicum, Cistus, Echinacea, Galphimia, Hedera, Melia, Olea, Pelargonium, Phytolacca, Primula, Salix, Thymus, Vitex , and Vitis ; and to a mixture thereof and to a method of production and the use thereof. The invention further relates to an agent and drug obtainable on the basis of the hydrolyzate.

1 . A hydrolyzate comprising at least one extract, which is produced by extraction from dried plant material of:
 a.) at least one of the plants, selected from the group consisting of at least one genus:     Equiseti, Juglandis, Millefolii, Quercus, Taraxaci, Althaeae, Matricariae, Centaurium, Levisticum, Rosmarinus, Angelica ( e ),  Artemisia, Astragalus, Leonurus, Salvia, Saposhnikovia, Scutellaria, Siegesbeckia, Armoracia, Capsicum, Cistus, Echinacea, Galphimia, Hedera, Melia, Olea, Pelargonium, Phytolacca, Primula, Salix, Thymus, Vitex , or  Vitis;      and a mixture thereof; or   b.) at least one of the plants, selected from the group consisting of at least one species:     Equiseti herba  (horsetail herb),  Juglandis folium  (walnut leaf),  Millefolii herba  (yarrow),  Quercus cortex  (oak bark),  Taraxaci herba  (dandelion herb),  Althaeae radix  (marshmallow root),  Matricariae flos  (or  Flos chamomillae  (chamomile flower)),  Centaurium erythraea  (centaury),  Levisticum officinale  (lovage),  Rosmarinus officinalis  (rosemary),  Angelica dahurica  (Dahurican angelica),  Angelica sinensis  (Chinese angelica),  Artemisia scoparia  (redstem wormwood),  Astragalus membranaceus  (var.  Mongolicus ) (Chinese milkvetch),  Leonurus japonicus  (Chinese motherwort),  Salvia miltiorrhiza  (red sage),  Saposhnikovia divaricata  (siler),  Scutellaria baicalensis  (Baikal skullcap),  Siegesbeckia pubescens  (Siegesbeckia herb),  Armoracia rusticana  (horseradish),  Capsicum  sp. (peppers),  Cistus incanus  (hairy rockrose),  Echinacea angustifolia  (blacksamson echinacea),  Echinacea purpurea  (purple coneflower),  Galphimia glauca, Hedera helix  (English ivy),  Melia toosendan  (chinaberry fruit),  Olea europaea  (olive),  Pelargonium  sp. (geranium),  Phytolacca americana  (American pokeweed),  Primula veris  (cowslip),  Salix  sp. (willow),  Thymus  L (thyme),  Vitex agnus castus  (lilac chastetree), and  Vitis vinifera  (common grape vine); and a mixture thereof; or   c.) in particular a mixture of:     Centaurium erythraea  (centaury),  Levisticum officinale  (lovage) and  Rosmarinus officinalis  (rosemary);   d.)  Equiseti herba  (horsetail herb),  Juglandis folium  (walnut leaf),  Millefolii herba  (yarrow),  Quercus cortex  (oak bark),  Taraxaci herba  (dandelion herb),  Althaeae radix  (marshmallow root), and  Matricariae flos  (or  Flos chamomillae  (chamomile flower));   e.)  Thymus  L. (thyme),  Primula veris  (cowslip) and/or  Hedera helix  (English ivy);   wherein the hydrolyzate can be obtained from the extract by way of hydrolytic treatment using a mineral acid.   
     
     
         2 . The hydrolyzate according to  claim 1 , wherein the extracts can be produced from the plant material using an extracting agent comprising 40 to 60% by volume ethanol and 40 to 60% by volume water over 6 hours to 36 hours, more particularly 12 to 30 hours, while stirring and optionally vacuum evaporation of the solvent. 
     
     
         3 . The hydrolyzate according to  claim 1 , wherein it can be obtained by the hydrolytic treatment of the extracts with hydrochloric acid as the mineral acid, in particular in a concentration of 1 M to 10 M, preferably 6 to 9 M, at 80° C. to 100° C., for 30 minutes to 120 minutes, in particular 40 minutes to 60 minutes, and/or the final solution has a concentration of the hydrochloric acid of 1 to 4 M, in particular 1 to 2 M, and more particularly 1.3 M. 
     
     
         4 . A hydrolyzate according to  claim 1 , wherein the hydrolyzate exhibits an antibacterial effect. 
     
     
         5 . A hydrolyzate according to  claim 1 , wherein the hydrolyzate is present in the form of a dry mass or aqueous suspension, and optionally is present in neutralized form. 
     
     
         6 . A hydrolyzate according to  claim 1 , wherein the antibacterial effect, as compared to the non-hydrolytically treated pure plant drugs, in terms of the therapeutic range thereof is comparable to an antibiotic control agent comprising amoxicillin and clavulanic acid (mass ratio 6:1). 
     
     
         7 . A hydrolyzate according to  claim 1 , wherein the antibacterial effect is directed against skin, ENT and respiratory tract relevant bacteria, in particular gram positive cocci, more particularly  Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus mutans  and/or gram negative rod bacteria, more particularly  Haemophilus influenzae  and/or MRSA (methicillin-resistant  Staphylococcus aureus ). 
     
     
         8 . A hydrolyzate according to  claim 1 , wherein it is present in a pharmaceutical formulation, more particularly an oral formulation such as sugar-coated tablets, tablets, film-coated tablets, capsules, liquid dilutions, more particularly drops, juices, syrups, or a formulation for topical application such as sprays, ointments, emulsions, powder, ground material, liquid or solid preparations for inhalation, compresses, wound and gum dressings, tamponades, tonsil brush solutions, gargling solutions or rinsing solutions for the nose and ears, or a lyophilizate. 
     
     
         9 . An antibacterial agent containing a hydrolyzate according to  claim 1 . 
     
     
         10 . A pharmaceutical compound containing a hydrolyzate according to  claim 1 , in the form of powder, granules, a tablet, or in liquid form as acid, aqueous, aqueous-acid, aqueous-organic, aqueous-acid-organic, aqueous-alcoholic, aqueous-acid-alcoholic or organic formulations, in particular in the form of a pharmaceutical formulation, more particularly an oral formulation such as sugar-coated tablets, tablets, film-coated tablets, capsules, liquid dilutions, more particularly drops, juices, syrups, or a formulation for topical application such as sprays, ointments, emulsions, powder, ground material, liquid or solid preparations for inhalation, compresses, wound and gum dressings, tamponades, tonsil brush solutions, gargling solutions or rinsing solutions for the nose and ears, or a lyophilizate, including additives and adjuvants. 
     
     
         11 . A pharmaceutical product comprising an antibacterial agent according to  claim 9  for the prophylaxis and treatment of infections, in particular respiratory tract infections, and more particularly tonsillitis, sinusitis, and rhinitis.